Lyra Therapeutics
Update in progressLYRA (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing anti-inflammatory therapies for chronic rhinosinusitis. Its approach delivers medicines directly to the affected tissue for sustained effect after a single administration. Lead candidate LYR-210 is an implantable anti-inflammatory drug matrix in Phase III for CRS; LYR-220 targets patients needing ongoing symptom control. The company collaborates with LianBio for several Asian markets and is based in Watertown, MA.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.33
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCPK (PNK)
- LocationUnited States
- Founded2005
- Employees27
- Websitelyratherapeutics.com
Identifiers
- ISINUS55234L1052
- FIGIBBG001J2N202
- CUSIP55234L105
- CIK0001327273